Carisma Therapeutics Inc. CARM
- Market cap
- $1.5M
- P/E
- 0.0×
Follow CARM
Target Price Range
Analyst price targets
Free account| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | 5.02 | 12.40 | 15.00 | 13.22 | 7.40 | 14.00 | 7.30 | 2.18 | 0.38 |
Analyst estimates 2025–2027 Powerpack |
Low Price
|
||
| — | 119.40 | 50.80 | 70.00 | 52.00 | 36.40 | 120.80 | 19.30 | 13.00 | 3.06 |
High Price
|
|||
| — | 35 | 17 | 24 | 25 | 27 | 35 | 17 | 107 | 46 |
Employees
|
|||
| — | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
Revenue/Emp
|
|||
| — | 30 | 0 | — | — | 11 | 27 | 10 | 15 | 20 |
Revenue
|
|||
| — | 100.00% | 100.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Gross Margin
|
|||
| — | 2 | (29) | (34) | (107) | (21) | (9) | (61) | (87) | (60) |
EBT
|
|||
| — | 6.32% | (6,830.35%) | 0.00% | 0.00% | (186.47%) | (32.43%) | (622.60%) | (582.34%) | (308.05%) |
EBT Margin
|
|||
| — | 2 | (29) | (34) | (107) | (22) | 0 | (61) | (87) | (60) |
Net Income
|
|||
| — | 0 | 0 | 0 | 0 | 0 | 32 | 4 | 4 | 3 |
Depreciation
|
|||
| — | 28.44 | 0.33 | 0.00 | 0.00 | 1.90 | 2.91 | 4.62 | 0.45 | 0.47 |
Revenue/Sh
|
|||
| — | 1.80 | (22.20) | (11.00) | (23.60) | (3.80) | (0.04) | (28.77) | (2.59) | (1.45) |
Earnings/Sh
|
|||
| — | 2.41 | (13.61) | (7.39) | (8.25) | (5.22) | (7.56) | (2.40) | (2.42) | (1.45) |
Cash Flow/Sh
|
|||
| — | 0.31 | 0.08 | 0.00 | (0.03) | 0.00 | 0.00 | (2.19) | (0.03) | 0.00 |
Capex/Sh
|
|||
| — | 2.72 | (13.53) | (7.39) | (8.28) | (5.22) | (7.56) | (4.59) | (2.46) | (1.45) |
Free CF/Sh
|
|||
| — | 36.69 | 13.82 | 14.31 | (5.87) | (1.56) | 18.84 | (67.04) | 0.79 | (0.67) |
Book Value/Sh
|
|||
| — | 1 | 1 | 3 | 5 | 6 | 9 | 2 | 34 | 41 |
Shares
|
|||
| — | 24.88 | 0.00 | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| — | 1.40 | 0.72 | — | — | 3.88 | 3.93 | 2.77 | 6.38 | 0.89 |
PS Ratio
|
|||
| — | 1.08 | 1.20 | — | — | 0.00 | 0.87 | 0.00 | 3.59 | 0.00 |
PB Ratio
|
|||
| — | 0.56 | 0.24 | — | — | 2.54 | (0.37) | 1.00 | 1.20 | (0.02) |
EV/Sales
|
|||
| — | 5.85 | (0.40) | — | — | (3.37) | 0.20 | (1.00) | (0.22) | 0.01 |
EV/FCF
|
|||
| — | 3 | (18) | (23) | (38) | (31) | (69) | (5) | (81) | (60) |
Op' Cash Flow
|
|||
| — | 0 | 0 | 0 | 0 | 0 | 0 | (5) | (1) | 0 |
Capex
|
|||
| — | 3 | (18) | (23) | (38) | (31) | (69) | (10) | (82) | (60) |
FCF
|
|||
| — | 22 | 10 | 46 | 46 | 45 | 194 | 35 | 65 | 8 |
Working Cap'
|
|||
| — | — | — | — | — | — | — | 35 | 0 | 0 |
Total Debt
|
|||
| — | (25) | (15) | (50) | (48) | (55) | (163) | (17) | (77) | (18) |
Net Debt
|
|||
| — | 39 | 18 | 44 | (27) | (9) | 172 | (143) | 27 | (28) |
Sh' Equity
|
|||
| — | 2.68% | (32.40%) | (36.10%) | (95.16%) | (19.01%) | (0.18%) | (39.13%) | (107.45%) | (100.78%) |
ROA
|
|||
| — | 13.43% | (545.15%) | 0.00% | 0.00% | 0.00% | (58.88%) | 0.00% | 0.00% | 0.00% |
ROIC
|
|||
| — | 6.56% | (102.38%) | (108.27%) | (1,228.08%) | 125.50% | (0.41%) | (421.67%) | 149.61% | 8,783.88% |
ROE
|
|||
Carisma Therapeutics Inc. peers in Biotechnology
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| FNCHQ Finch Therapeutics Group, Inc. | $1.6M | 0.0× | Compare |
| ITRMF Iterum Therapeutics PLC | $1.6M | 0.0× | Compare |
| NEXI NexImmune, Inc. | $1.6M | 0.0× | Compare |
| SLXN Silexion Therapeutics Corp | $1.4M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| ABPO Abpro Holdings Inc. | $1.4M | 0.2× | Compare |
| BBLG Bone Biologics Corp. | $1.4M | 0.0× | Compare |
| TRVN Trevena, Inc. | $1.8M | 0.0× | Compare |
| PTIX Atrinsic Inc. | $1.3M | 0.3× | Compare |
Carisma Therapeutics Inc. (CARM) Latest News
29 Jul
Carisma Therapeutics Inc. (CARM) released its H1 2026 financial results. Half-year results provide updated financial metrics that can shift near-term investor views on operations.
6 Mar
Liberate Bio has licensed myeloid-specific CAR design patents from Carisma Therapeutics Inc. (CARM), enabling development of next-generation CAR therapies targeting myeloid cells. Licensing core IP for myeloid CAR designs generates potential revenue, validates Carisma's technology, and strengthens its position in immunotherapy.
Liberate Bio acquires licenses for myeloid-specific CAR design patents from Carisma Therapeutics Inc. (CARM). Licensing core myeloid CAR patents to Liberate Bio validates CARM's technology and may provide moderate revenue potential without fundamentally altering its trajectory.
5 Dec
Carisma Therapeutics Inc. (CARM) has announced its delisting from the Nasdaq stock exchange and will also deregister with the SEC. This decision follows the company's strategic evaluation and is part of its efforts to streamline operations and reduce costs. The delisting is effective immediately, and the company will no longer be subject to the reporting requirements of the SEC. Delisting from Nasdaq and SEC deregistration may limit access to capital and affect investor sentiment.
9 Sep
Recent retail leasing momentum is expected to positively influence Carmila’s share price by 2025, as increased consumer activity and foot traffic could enhance the performance of retail properties. This trend may lead to higher rental income and improved valuations, benefiting investors and stakeholders in the retail sector. Increased retail leasing activity may moderately influence Carmila's financial performance and market sentiment.
8 Sep
Carisma Therapeutics Inc. (CARM) has been identified as one of the most active stocks in the market, reflecting heightened trading activity and investor interest. The company's recent developments and market movements have contributed to its visibility among investors, indicating potential shifts in market sentiment and engagement with its stock. Increased trading activity suggests a moderate influence on market sentiment and potential interest in the company's future performance.
2 Sep
Carisma Therapeutics Inc. (CARM) has been identified as one of the most active stocks in the market, indicating heightened trading activity and investor interest. This surge in activity may reflect broader market trends or specific developments related to the company's operations or strategic initiatives. Increased trading activity suggests a moderately noticeable influence on market sentiment and potential financial performance.
24 Jun
Carisma Therapeutics (CARM) and OrthoCellix, a subsidiary of Ocugen (OCGN), have entered into a definitive merger agreement in an all-stock transaction. The combined entity will focus on OrthoCellix’s NeoCart technology for treating knee cartilage defects, with plans to initiate a Phase 3 clinical trial by the end of 2025. OrthoCellix's NeoCart utilizes patient cells to create cartilage implants, potentially accelerating healing and reducing pain. Following the merger, OrthoCellix will remain a subsidiary of Carisma, which will issue shares to OrthoCellix stockholders. The merger is expected to close in the second half of 2025, pending stockholder approvals and regulatory conditions, with Carisma set to be renamed OrthoCellix, Inc. and trade under the ticker symbol 'OCLX.' The merger represents a significant strategic move that could enhance product development and market positioning for the combined company.
23 Jun
Carisma Therapeutics Inc. has entered into a definitive merger agreement with OrthoCellix to form a new company focused on regenerative cell therapies for orthopedic diseases. This strategic move aims to enhance the development and commercialization of innovative treatments in the orthopedic sector, leveraging both companies' expertise and resources. The merger is a significant strategic move that could enhance product offerings and market positioning in the regenerative medicine field.
2 Apr
Carisma Therapeutics (NASDAQ:CARM) reported a full year 2024 revenue of US$19.6 million, a 32% increase from FY 2023, but missed analyst estimates by 8.3%. The net loss narrowed to US$60.5 million, with a loss per share of US$1.46, an improvement from US$2.59 in FY 2023. However, earnings per share also fell short of expectations by 22%. Looking ahead, revenue is projected to decline by 57% annually over the next three years, contrasting with a 19% growth forecast for the US biotech industry. The company's shares have dropped 42% in the past week, and there are five warning signs identified, two of which are significant. The significant revenue decline forecast and missed earnings expectations indicate potential challenges that could alter the company's trajectory.
31 Mar
Carisma Therapeutics Inc. provided updates on its corporate activities, highlighting advancements in its pipeline and strategic initiatives aimed at enhancing its market position. The company is focused on developing innovative therapies and has made progress in its clinical trials, which are expected to drive future growth. Additionally, Carisma is exploring partnerships to expand its reach and capabilities in the biopharmaceutical sector. Significant advancements in clinical trials and strategic initiatives are likely to impact the company's future performance and market position.
9 Dec
Carisma Therapeutics announces strategic restructuring to re-prioritize pipeline. The strategic restructuring of Carisma Therapeutics is expected to significantly impact its future trajectory and market performance.
27 Nov
Carisma Therapeutics Inc. will participate in the 7th Annual Evercore ISI HealthCONx Conference with a fireside chat by the CEO. Participation in the conference may moderately influence investor sentiment and competitive positioning.
17 Nov
Carisma Therapeutics presented promising preclinical data on engineered macrophages for treating liver fibrosis at AASLD The Liver Meeting® 2024. The preclinical data presented could lead to significant advancements in the treatment of liver fibrosis, impacting Carisma Therapeutics' future development and market performance.
8 Nov
Carisma Therapeutics Inc. unveils promising pre-clinical data on anti-GPC3 in vivo CAR-M therapy for hepatocellular carcinoma. The significant impact is likely on future performance due to the potential of the therapy for hepatocellular carcinoma.
7 Nov
Carisma Therapeutics reports Q3 2024 financial results and business highlights. Financial results and business highlights may moderately influence company's performance.
5 Nov
Carisma Therapeutics will present new data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024. The presentation of new data on CAR-M therapy for hepatocellular carcinoma could have a significant impact on Carisma Therapeutics' future and market performance.
30 Oct
Carisma Therapeutics appoints Sohanya Cheng to its Board of Directors and announces Michael Torok's resignation due to other commitments. Appointment of a new board member and resignation of an existing member may moderately influence the company's strategic direction and operations.
4 Oct
Carisma Therapeutics Inc. announces upcoming poster presentations at SITC 2024 for two studies on anti-cancer therapies. The announcement of upcoming presentations at a major cancer conference could have a significant impact on Carisma's future and market performance.
10 Sep
Carisma Therapeutics and Moderna are expanding their collaboration into autoimmune diseases. The collaboration expansion into autoimmune diseases signifies a significant strategic move that could alter Carisma Therapeutics' trajectory and market sentiment.
Carisma Therapeutics Inc. expands collaboration with Moderna to develop two in vivo CAR-M therapies for autoimmune diseases, with Carisma retaining rights to other autoimmune targets. The expanded collaboration with Moderna to develop therapies for autoimmune diseases has the potential to significantly impact Carisma's future product pipeline and market positioning.
3 Sep
Carisma Therapeutics Inc. will present at upcoming conferences to discuss their innovative immunotherapies. Participation in conferences may moderately influence key areas such as financial performance and competitive positioning.
13 Aug
Carisma Therapeutics Inc. (CARM) upgraded to Zacks Rank #2 (Buy) due to positive earnings outlook and rising estimates. The article highlights the potential significant impact of the upgraded Zacks Rank on the company's future stock performance.
8 Aug
Carisma Therapeutics Inc. reported financial results for the second quarter of 2024, highlighting progress in their lead product candidate for anti-HER2 program and nomination of a development candidate for liver fibrosis program. The article discusses significant advancements in Carisma's development pipeline and collaborations, which are expected to have a major impact on the company's future performance.
Carisma Therapeutics Inc. (CARM) reported a Q2 loss of $0.27 per share, beating revenue estimates by 151.97% with $9.2 million in revenues. The article suggests a moderately noticeable influence on Carisma Therapeutics Inc. (CARM) future and market performance due to the earnings report.
6 Aug
Carisma Therapeutics Inc. announced an upcoming poster presentation at the AASLD The Liver Meeting® 2024, focusing on engineered macrophages for liver fibrosis. The presentation at AASLD 2024 could have a significant impact on Carisma's future developments and market performance.
Carisma Therapeutics appoints Dr. Scott Friedman and Dr. Ira Tabas to its Scientific Advisory Board for liver fibrosis expertise. Appointing renowned experts in liver fibrosis to the Scientific Advisory Board can significantly impact Carisma's development of innovative therapies for advanced liver disease.
3 Aug
Carisma Therapeutics had a cash runway of 9 months in March 2024, with increasing cash burn and revenue growth. The company's high cash burn relative to market cap raises funding distress concerns. The article highlights significant impact on Carisma Therapeutics' future and market performance due to high cash burn and potential funding distress.
1 Jul
Carisma Therapeutics announced changes to its Board of Directors, appointing David Scadden, M.D. and Marella Thorell while Regina Hodits and Björn Odlander resigned due to other commitments. Appointment of renowned experts and experienced professionals to the Board is expected to have a significant impact on Carisma Therapeutics' future and market performance.
27 Jun
Carisma Therapeutics Inc. announced the nomination of the first in vivo CAR-M development candidate targeting Glypican-3 for the treatment of solid tumors, including hepatocellular carcinoma, triggering a $2 million milestone payment. The nomination of the first in vivo CAR-M development candidate for hepatocellular carcinoma has the potential to significantly impact Carisma Therapeutics Inc.'s future and market performance.